Research Topic · Peer-Reviewed

Protease Inhibitor Therapy

Protease inhibitor therapy is a class of antiretroviral treatment that suppresses replication of the human immunodeficiency virus (HIV) by blocking the viral protease enzyme. HIV protease cleaves large precursor polyproteins into the functional structural proteins and enzymes required to assemble mature, infectious …

Curated from this journal's research 📚 10 peer-reviewed articles cited Cited 21× across the literature 🔖 ISSN 2324-7339 🗓 Reviewed July 2026

Overview

Protease inhibitor therapy is a class of antiretroviral treatment that suppresses replication of the human immunodeficiency virus (HIV) by blocking the viral protease enzyme. HIV protease cleaves large precursor polyproteins into the functional structural proteins and enzymes required to assemble mature, infectious virus particles. By binding the active site of this enzyme, protease inhibitors prevent that processing step, so newly produced virions remain immature and non-infectious, reducing viral load and helping to preserve immune function. These agents are rarely used alone; they form one pillar of combination antiretroviral therapy, given alongside reverse transcriptase inhibitors and other drug classes to attack the viral life cycle at multiple points and limit the emergence of resistance. Clinical research surrounding protease inhibitor therapy addresses HIV drug resistance and the genetic mutations that reduce susceptibility, regimen selection and adherence, adverse drug reactions, and treatment outcomes across diverse patient populations including children, adolescents, and adults in varied healthcare settings. Computational and molecular studies further explore inhibitor binding and the search for new protease-targeting compounds, including investigations of natural products through docking analyses. As a cornerstone of effective HIV management, protease inhibitor therapy contributes to durable viral suppression, prevention of disease progression, and reduced transmission when integrated into well-monitored combination regimens.

Research published in this journal

10 peer-reviewed articles, ranked by relevance. Each links to its DOI.

2014

Phytochemicals May Arrest HIV-1 Progression

Sharma B.Corresponding author
Department of Biochemistry, Faculty of Science,
Clinical Research In HIV AIDS And Prevention Cited by 5 doi:10.14302/issn.2324-7339.jcrhap-13-edt.1.3
2013

Pattern of Use of Highly Active Antiretroviral Therapy Regimens and Pattern of Occurrence of Adverse Drug Reactions in an Indian Human Immunodeficiency Virus Positive Patients

Rajesh RadhakrishnanCorresponding author
Radhakrishnan Rajesh M.Pharm, Asst Professor (Senior Grade), Department of Pharmacy Practice, Manipal College of pharmaceutical Sciences, Manipal University, Manipal- 576 104, Karnataka, India.
Clinical Research In HIV AIDS And Prevention Cited by 1 doi:10.14302/issn.2324-7339.jcrhap-12-174
2012

Dual Choice for Dual Target Anti-HIV Therapy

Marchand ChristopheCorresponding author
Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda
Clinical Research In HIV AIDS And Prevention Cited by 1 doi:10.14302/issn.2324-7339.jcrhap-12-edt.1.1

How this research is being cited

The 10 articles above have been cited 21 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.

A sample of recent works citing this journal's research on Protease Inhibitor Therapy, linking to each citing work.

Editorial oversight

Curated from peer-reviewed research published in Clinical Research In HIV AIDS And Prevention (ISSN 2324-7339).

Journal editorial board
Manoj Sarma · United States Mohammed Merzah · Hungary Marta Talavera · Spain

This page summarises published research for orientation; it is not medical or professional advice.